U.S. markets close in 2 hours 29 minutes

Icosavax, Inc. (ICVX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.06-2.65 (-9.56%)
As of 1:27PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close27.71
Open27.70
Bid25.01 x 900
Ask25.52 x 800
Day's Range25.06 - 28.00
52 Week Range21.70 - 49.99
Volume69,462
Avg. Volume347,523
Market Cap987.048M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-9.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Icosavax, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/03/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update

    - Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F antigen - - Raised $209.3 million in gross proceeds from an upsized IPO, funding operations through at least 2024 - SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its inno

  • GlobeNewswire

    Icosavax Appoints Elizabeth Bekiroğlu to General Counsel

    SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekiroğlu to General Counsel. “Elizabeth is an accomplished leader who has established an expertise in providing legal counsel to biotechnology and healthcare companies,” said Adam Simpson, Chief Executive Officer of Icosavax. “I a

  • GlobeNewswire

    Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus

    - Phase 1/1b clinical trial will assess the safety and immunogenicity of IVX-121 in healthy adults, including older adults -SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the initiation of a Phase 1/1b clinical trial of IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F a